<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266355</url>
  </required_header>
  <id_info>
    <org_study_id>1408014510</org_study_id>
    <nct_id>NCT02266355</nct_id>
  </id_info>
  <brief_title>Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction</brief_title>
  <official_title>A Pilot Study of the Role of Omalizumab (Xolair) in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction (HSR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study to evaluate the activity of omalizumab in the prevention of recurrent oxaliplatin
      hypersensitivity reaction (HSR) in oxaliplatin-sensitive patients. The study will also
      evaluate the safety of omalizumab (Xolair) when administered in this setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label single arm pilot study studying the effects of omalizumab in the
      treatment of oxaliplatin hypersensitivity reaction (HSR) for patients with stage IV GI
      cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Recurrent HSR</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Recurrent Oxaliplatin HSR in subjects treated with omalizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Omalizumab</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Evaluate the safety of omalizumab by assessment of frequency of adverse events and serious adverse events as categorized by CTCAE version 4</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>OmalizumabTreatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omalizumab (Xolair) 300 mg SQ every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Omalizumab 300 mg SQ every 2 weeks</description>
    <arm_group_label>OmalizumabTreatment Group</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically evident HSR to oxaliplatin, with symptoms of flushing, urticaria, pruritus,
             rash, and/or dyspnea without bronchospasm that emerge during or shortly after of
             oxaliplatin infusion

          -  Responding (complete or partial) or stable disease according to RECIST criteria while
             undergoing treatment with oxaliplatin containing regimen or need to resume an
             oxaliplatin based regimen in the setting of well-documented recent oxaliplatin
             hypersensitivity reaction

          -  Histologically confirmed stage IV GI cancer (AJCC 7th edition) currently sensitive to
             oxaliplatin containing chemotherapy regimen

          -  Age 18 years or older

          -  ECOG performance status 0-2

          -  Adequate bone marrow, liver, and kidney function. (WBC &gt; 1500 cells/uL, platelets &gt;
             50,000/uL, ALT/AST &lt; 5xULN (unless due to liver metastasis), Creatinine &lt; 2.0 mg/ld)

          -  Willing to give written informed consent, adhere to the visit schedules and meet study
             requirements

        Exclusion Criteria:

          -  Prior history of severe reactions to oxaliplatin as characterized by the presence of
             hemodynamic instability, significant respiratory symptoms or potential airway
             compromise

          -  History of hypersensitivity reaction to Xolair or any ingredient of Xolair

          -  Concurrent therapy with investigational agents

          -  Use of any other investigational agent in the last 15 days and all toxicity of prior
             therapy resolved

          -  Psychological, familial, or sociological condition potentially hampering compliance
             with the study protocol and follow-up schedule

          -  Women of childbearing potential not using the contraception method(s), as well as
             women who are breastfeeding

          -  Patients with severe medical conditions that in the view of the investigator prohibits
             participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Hochster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Howard Hochster, MD</last_name>
    <phone>203-785-5756</phone>
    <email>howard.hochster@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Howard S Hochster, MD</last_name>
    <phone>203-785-5756</phone>
    <email>howard.hochster@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Uboha, MD, PhD</last_name>
      <phone>475-202-9827</phone>
      <email>nataliya.uboha@yale.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxaliplatin</keyword>
  <keyword>Omalizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

